March 2015, Vol 8, Sixth Annual Payers' Guide

FDA Approvals, Payers' Guide

The Sixth Annual Payers’ Guide to New FDA Approvals

New FDA Drug Approvals Hit an 18-Year High in 2014

Gary M. Owens, MD

Drug Updates, Payers' Guide

FDA Approvals of Brand-Name Prescription Drugs in 2014

Drug Updates, Payers' Guide

Afrezza (Insulin Human) Inhalation Powder Approved for the Treatment of Patients with Type 1 or Type 2 Diabetes

Drug Updates, Payers' Guide

Akynzeo (Netupitant and Palonosetron), a Dual-Acting Oral Agent, Approved by the FDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting

Lisa A. Raedler, PhD, RPh

Drug Updates, Payers' Guide

Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non–Small-Cell Lung Cancer

Drug Updates, Payers' Guide

Once-a-Day Harvoni (Ledipasvir plus Sofosbuvir), a New Oral Combination for the Treament of Patients with Genotype 1 Chronic Hepatitis C Infection

Lisa A. Raedler, PhD, RPh

Drug Updates, Payers' Guide

Imbruvica (Ibrutinib), First-in-Class Bruton’s Tyrosine Kinase Inhibitor, Receives Expanded Indications for Patients with Relapsed Chronic Lymphocytic Leukemia

Lisa A. Raedler, PhD, RPh

Drug Updates, Payers' Guide

Invokamet (Canagliflozin plus Metformin HCl): First Fixed-Dose Combination with an SGLT2 Inhibitor Approved for the Treatment of Patients with Type 2 Diabetes

Drug Updates, Payers' Guide

Jakafi (Ruxolitinib): First FDA-Approved Medication for the Treatment of Patients with Polycythemia Vera

Lisa A. Raedler, PhD, RPh

1
2
3

Page 1 of 3
Results 1 - 10 of 27

SUBSCRIBE

© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

AHDB Print Edition

AHDB Weekly e‑Newsletter

I have reviewed and consent to the terms of AHDB's Privacy Policy, and AHDB has my permission to retain my information in its database, and to forward pertinent communications to me.